New Data Shed Further Light On HCV Protease Race
Executive Summary
Recently presented and published final Phase II data have set the stage for the ultimate chapter in a compelling race to successfully develop the first hepatitis C protease inhibitor. These first-generation molecules from Vertex Pharmaceuticals and Schering-Plough are not perfect, but look likely to significantly improve HCV cure rates and potentially establish strikingly shorter durations for difficult-to-take therapeutic regimens
You may also be interested in...
Vertex Advances Toward Telaprevir Approval
The first Phase III results for the hepatitis C direct-acting antiviral give the firm reason to be confident.
Sponsors Caution Against Premature Expanded Access For Novel HCV Drugs
Early positive trial results for direct-acting antivirals for Hepatitis C, combined with the seriousness of the disease and unmet clinical need, make Hep C an obvious target for expanded access programs.
Sponsors Caution Against Premature Expanded Access For Novel HCV Drugs
Early positive trial results for direct-acting antivirals for Hepatitis C, combined with the seriousness of the disease and unmet clinical need, make Hep C an obvious target for expanded access programs.